Smoking remains the leading cause of preventable death worldwide, and yet quitting remains genuinely difficult for most people who try. A systematic review published in the journal Addiction by the Cochrane Tobacco Addiction Group at the University of Oxford offers the clearest picture yet of which strategies actually move the needle, drawing on studies conducted between 2021 and 2023.
The central finding is straightforward. Three approaches consistently outperformed the rest: varenicline, cytisine and nicotine e-cigarettes. Layered on top of any of them, behavioral therapy and financial incentives pushed quit rates higher still.
The medications leading the field
Varenicline is a prescription oral tablet that works by binding to nicotine receptors in the brain, reducing both cravings and the severity of withdrawal symptoms. Among all the medications reviewed, it performed most consistently. It outperformed bupropion and most forms of nicotine replacement therapy in head-to-head comparisons, though the review notes it may carry a higher risk of serious side effects than some alternatives and should be used under medical supervision.
Cytisine, a plant-derived medication widely available in Canada and Europe but less accessible in the United States, works through a similar mechanism. It has gained significant attention in recent years as a lower-cost option with a strong evidence base. Researchers view it as one of the most promising underutilized tools in smoking cessation globally.
Bupropion, an antidepressant with established quit-smoking applications, also showed meaningful effectiveness compared to a placebo. It is a reasonable option for people who cannot tolerate varenicline, though it carries its own profile of potential psychiatric side effects that require monitoring.
Nicotine replacement therapy in its various forms, including patches, gums and lozenges, remains a widely used and reasonably effective option, though the Oxford review suggests it performs below varenicline and cytisine when used in single-form applications.
What behavioral support adds
Medication alone is not the complete picture. The review found that behavioral interventions meaningfully increased quit rates even when used without any pharmacological support. Combining elements such as text message programs, motivational counseling and structured follow-up contact appeared to improve outcomes beyond what either approach achieved on its own.
Mindfulness-based therapies were also examined. The evidence did not show a clear benefit or harm from these approaches, and the researchers called for further study before drawing conclusions about their role in cessation programs.
E-cigarettes and heated tobacco products
Nicotine-containing e-cigarettes showed higher quit rates in the review compared to traditional nicotine replacement therapy. That finding has practical significance given how widely e-cigarettes are already used as cessation tools by people who have never been formally directed toward them.
The researchers were careful to note that while e-cigarettes appear to reduce exposure to many of the harmful chemicals found in combustible tobacco, the long-term safety profile remains incompletely understood. More independent research is needed before firm conclusions about their use can be drawn.
Heated tobacco products, which deliver nicotine through an aerosol rather than combustion, were also flagged for further study. The review’s authors called specifically for research conducted independent of tobacco industry funding to assess whether these products offer genuine cessation benefits or primarily serve as a bridge between cigarettes and continued nicotine dependence.
Smoking and mental health
The relationship between smoking and mental health conditions adds complexity to cessation efforts. Smoking rates are disproportionately high among people living with anxiety, depression and other psychiatric conditions. The assumption that nicotine helps manage these symptoms is widespread but largely inverted by the evidence. While nicotine produces short-term relief from anxiety, it contributes to elevated baseline anxiety and stress levels over time, creating a cycle that makes quitting feel riskier than it is.
Quitting smoking has been linked to improvements in mental health outcomes, not just physical ones. That finding suggests cessation programs designed for people with mental health conditions need to address both dimensions rather than treating them separately.
The Oxford review makes clear that effective tools exist and that the combination of the right medication, consistent behavioral support and informed guidance from a healthcare provider gives people the best realistic chance of quitting for good.
